Monitor for future filings disclosing the terms of the Series B Preferred Stock offering, including size, pricing, and use of proceeds, which could impact equity dilution and company valuation.
How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Mar 3 $0.1160entry
- T+1 · 9mo ago +6.03%α +5.27% · $0.1230
- T+5 · 9mo ago +12.93%α +13.41% · $0.1310
- T+20 · 8mo ago +11.21%α +15.61% · $0.1290
- T+60 · 6mo ago +1.72%α −8.59% · $0.1180
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
SRx Health Solutions obtained waivers from existing investors to proceed with a new preferred stock offering (Series B), allowing the company to issue new securities and waive existing participation rights. The Series B Preferred Stock will rank pari passu with the existing Series A Preferred Stock in terms of dividend and liquidation preferences.
Key Facts
- SRx Health Solutions entered into limited waiver and consent agreements with existing investors to permit a new securities offering (New Offering).
- The New Offering involves the issuance of Series B Preferred Stock and related warrants to new accredited investors.
- Existing investors waived their right of participation in the New Offering and any subsequent placements.
- Certain existing investors, as Required Holders, consented to the Series B Preferred Stock ranking pari passu with the Series A Preferred Stock regarding dividends, distributions, and liquidation preferences.
- No financial terms of the New Offering (e.g., size, price, valuation) were disclosed in this filing.
Financial Impact
Potential future capital raise via Series B Preferred Stock offering, but no financial terms disclosed.
Risk Factors
- Future dilution to common shareholders upon issuance of Series B Preferred Stock and exercise of related warrants.
- Potential for unfavorable terms in the New Offering that may not be disclosed until closing.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001493152-26-008656 |
| Exhibit: ex10-1.htm | 0001493152-26-008656 |
| Document: 0001493152-26-008656-index-headers.html | 0001493152-26-008656 |
| Document: 0001493152-26-008656-index.html | 0001493152-26-008656 |
| Document: 0001493152-26-008656.txt | 0001493152-26-008656 |
Track record
30 reports on SRXH
4 of 6 bullish or bearish reports moved the stock their way by T+5. Best: +77.11% at T+60 after the Jun 18, 2026 report. 4 of 6 went positive at some point.
Filters
- Nov 20, 20261d ago Press Release Neutral 3/10 Entry $0.8402 Now $0.8000 −4.78% settles Nov 30
- Nov 20, 20261d ago SC 13D Neutral 5/10 Entry $0.9950 Now $0.8000 −19.60% settles Nov 30
- Oct 30, 202622d ago Press Release Neutral 3/10 Entry $1.01 to $0.8116 Now $0.8000 −20.79% ▼ −19.64% −16.94% vs SPY
- Oct 7, 20266w ago 8-K Mixed 6/10 Entry $1.49 to $1.29 Now $0.8000 −46.31% ▼ −13.42% −12.44% vs SPY
- Oct 6, 20266w ago 8-K Neutral 4/10 Entry $1.49 to $1.29 Now $0.8000 −46.31% ▼ −13.42% −12.44% vs SPY
- Sep 24, 20268w ago Press Release Neutral 3/10 Entry $1.73 to $1.61 Now $0.8000 −53.76% ▼ −6.94% −6.52% vs SPY
- Sep 9, 202610w ago 8-K Neutral 3/10 Entry $1.51 to $1.60 Now $0.8000 −47.02% ▲ +5.96% +6.62% vs SPY
- Sep 2, 202611w ago 8-K Neutral 5/10 Entry $1.56 to $1.59 Now $0.8000 −48.72% ▲ +1.92% +3.07% vs SPY
- Aug 28, 202612w ago 8-K Bearish 5/10 Entry $1.68 to $1.59 Now $0.8000 +52.38% ▲ +5.65% +5.51% vs SPY
- Aug 19, 202613w ago 8-K Mixed 5/10 Entry $1.87 to $1.84 Now $0.8000 −57.22% ▼ −1.60% −1.22% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers